Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Byun HS et al. | Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells. | 2013 | Medchemcomm | pmid:24396570 |
Baird RD et al. | Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. | 2009 | Mol. Cancer Ther. | pmid:19509256 |
Den Brok MW et al. | Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl. | 2005 Jul-Aug | PDA J Pharm Sci Technol | pmid:16218203 |
Den Brok MW et al. | Compatibility and stability of the novel anticancer agent ES-285 x HCl formulated with 2-hydroxypropyl-beta-cyclodextrin in infusion devices. | 2006 | Pharmazie | pmid:16454201 |
Faircloth G and Cuevas C | Kahalalide F and ES285: potent anticancer agents from marine molluscs. | 2006 | Prog. Mol. Subcell. Biol. | pmid:17153351 |